Estramustine plus docetaxel as second-line therapy in patients with hormone-refractory prostate cancer resistant to docetaxel alone

Urologic Oncology: Seminars and Original Investigations

Volumn 28, Issue 2, 2010, Pages 152-156

  Caffo, Orazio ^a   Sava, Teodoro ^b   Comploj, Evi ^c   Giampaolo, Maria Anna ^d   Segati, Romana ^d   Valduga, Francesco ^a   Cetto, Gianluigi ^b   Galligioni, Enzo ^a  

^a SANTA CHIARA HOSPITAL   (Italy)

^b UNIVERSITY OF VERONA   (Italy)

^c San Maurizio Regional Hospital   (Italy)

^d Civil Hospital   (Italy)

Author keywords

Docetaxel; Estramustine phosphate; Hormone refractory prostate cancer; Second line therapy

Indexed keywords

DOCETAXEL; ESTRAMUSTINE; PREDNISOLONE;

ADULT; AGED; ALOPECIA; ANOREXIA; ARTHRALGIA; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER SURVIVAL; CEREBROVASCULAR ACCIDENT; CLINICAL ARTICLE; CLINICAL TRIAL; CONJUNCTIVITIS; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; DIARRHEA; EDEMA; FATIGUE; HUMAN; LIVER TOXICITY; MALE; MUCOSA INFLAMMATION; NAUSEA; NEPHROTOXICITY; PATIENT COMPLIANCE; PHASE 2 CLINICAL TRIAL; PNEUMONIA; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROSTATE CANCER; RANDOMIZED CONTROLLED TRIAL; SENSORY NEUROPATHY; SIDE EFFECT; TASTE DISORDER; TREATMENT RESPONSE; VOMITING; WEIGHT REDUCTION;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CLINICAL TRIALS, PHASE II AS TOPIC; DRUG RESISTANCE, NEOPLASM; ESTRAMUSTINE; HUMANS; MALE; MIDDLE AGED; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TAXOIDS;

EID: 77249176173     PISSN: 10781439     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.urolonc.2008.07.033     Document Type: Article

References (21)

1. Tannock I.F., de Wit R., Berry W.R., et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 351 (2004) 1502-1512
2. Petrylak D.P., Tangen C.M., Hussain M.H., et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 351 (2004) 1513-1520
3. Sartor O., Petrylak D.P., Witjes J.A., et al. Satraplatin in patients with advanced hormone-refractory prostate cancer (HRPC): Overall survival (OS) results from the Phase III satraplatin and prednisone against refractory cancer (SPARC) trial. Proc Am Soc Clin Oncol 26 (2008) abstr 5003
4. Di Lorenzo G., Figg W.D., Fossa S.D., et al. Combination of Bevacizumab and Docetaxel in Docetaxel-Pretreated Hormone-Refractory Prostate Cancer: A Phase 2 Study. Eur Urol 54 (2008) 1089-1094
5. Nakabayashi M., Sartor O., Jacobus S., et al. Response to docetaxel/carboplatin-based chemotherapy as first- and second-line therapy in patients with metastatic hormone-refractory prostate cancer. BJU Int 101 (2008) 308-312
6. Ross R.W., Beer T.M., Jacobus S., et al. A Phase 2 study of carboplatin plus docetaxel in men with metastatic hormone-refractory prostate cancer who are refractory to docetaxel. Cancer 112 (2008) 521-526
7. Hudes G., Einhorn L., Ross E., et al. Vinblastine vs. vinblastine plus oral estramustine phosphate for patients with hormone-refractory prostate cancer: A Hoosier Oncology Group and Fox Chase Network Phase III trial. J Clin Oncol 17 (1999) 3160-3166
8. Berry W.R., Hathorn J.W., Dakhil S.R., et al. Phase II randomized trial of weekly paclitaxel with or without estramustine phosphate in progressive, metastatic, hormone-refractory prostate cancer. Clin Prostate Cancer 3 (2004) 104-111
9. Eymard J.C., Priou F., Zannetti A., et al. Randomized Phase II study of docetaxel plus estramustine and single-agent docetaxel in patients with metastatic hormone-refractory prostate cancer. Ann Oncol 18 (2007) 1064-1070
10. Caffo O., Sava T., Comploj E., et al. Docetaxel, with or without estramustine phosphate, as first-line chemotherapy for hormone-refractory prostate cancer: Results of a multicenter, randomized Phase II trial. BJU Int 102 (2008) 1080-1085
11. Montgomery R.B., Nelson P.S., Lin D., et al. Diethylstilbestrol and docetaxel: A Phase II study of tubulin active agents in patients with metastatic, androgen-independent prostate cancer. Cancer 110 (2007) 996-1002
12. Fizazi K., Le M.A., Hudes G., et al. Addition of estramustine to chemotherapy and survival of patients with castration-refractory prostate cancer: A meta-analysis of individual patient data. Lancet Oncol 8 (2007) 994-1000
13. Heidenreich A., Aus G., and Bolla M. EAU guidelines on prostate cancer. Eur Urol 53 (2008) 68-80
14. Bubley G.J., Carducci M., Dahut W., et al. Eligibility and response guidelines for Phase II clinical trials in androgen-independent prostate cancer: Recommendations from the Prostate-Specific Antigen Working Group. J Clin Oncol 17 (1999) 3461-3467
15. Therasse P. Measuring the clinical response. What does it mean?. Eur J Cancer 38 (2002) 1817-1823
16. Oudard S., Legrier M.E., Boye K., et al. Activity of docetaxel with or without estramustine phosphate versus mitoxantrone in androgen dependent and independent human prostate cancer xenografts. J Urol 169 (2003) 1729-1734
17. Petrylak D.P., Macarthur R., O'Connor J., et al. Phase I/II studies of docetaxel (Taxotere) combined with estramustine in men with hormone-refractory prostate cancer. Semin Oncol 26 5 Suppl 17 (1999) 28-33
18. Sitka C.M., Ledakis P., Lynch J., et al. Weekly docetaxel and estramustine in patients with hormone-refractory prostate cancer. Semin Oncol 28 4 Suppl 15 (2001) 16-21
19. Savarese D.M., Halabi S., Hars V., et al. Phase II study of docetaxel, estramustine, and low-dose hydrocortisone in men with hormone-refractory prostate cancer: A final report of CALGB 9780. Cancer and Leukemia Group B. J Clin Oncol 19 (2001) 2509-2516
20. Sinibaldi V.J., Carducci M.A., Moore-Cooper S., et al. Phase II evaluation of docetaxel plus one-day oral estramustine phosphate in the treatment of patients with androgen independent prostate carcinoma. Cancer 94 (2002) 1457-1465
21. Oudard S., Banu E., Beuzeboc P., et al. Multicenter randomized Phase II study of two schedules of docetaxel, estramustine, and prednisone vs. mitoxantrone plus prednisone in patients with metastatic hormone-refractory prostate cancer. J Clin Oncol 23 (2005) 3343-3351